ResMed Inc. has terminated KPMG as its independent auditor, appointing PricewaterhouseCoopers LLP for the fiscal year ending June 30, 2027. This transition indicates a strategic move towards new auditing capabilities, potentially impacting investor confidence.

Key Highlights

  • ResMed Inc. dismissed KPMG on August 13, 2026, effective immediately.
  • There were no disagreements or reportable events between ResMed Inc. and KPMG during their tenure.
  • ResMed Inc. has officially transitioned its auditing responsibilities, having dismissed KPMG as its independent auditor effective August 13, 2026.

ResMed Inc. has officially transitioned its auditing responsibilities, having dismissed KPMG as its independent auditor effective August 13, 2026. The move comes as part of a broader effort to ensure RESMED INC (NYSE: RMD)’s financial reporting meets its ongoing strategic objectives. This transition signifies a shift in external audit oversight for the leading health technology firm.

Appointment of New Auditor

Following the dismissal of KPMG, ResMed Inc. has selected PricewaterhouseCoopers LLP (PwC) to take over as its independent registered public accounting firm. This change is slated to commence from the fiscal year ending June 30, 2027. The Audit Committee conducted a competitive review process prior to this decision, which reflects a commitment to maintaining strong financial governance.

PwC’s appointment is contingent upon meeting its standard client acceptance protocols.

Historical Audit Performance

The audit reports from KPMG were not qualified or modified concerning matters of uncertainty, audit scope, or accounting principles. This consistent audit performance, free from disagreements or reportable events as defined by the Securities and Exchange Commission regulations, suggests a solid foundation laid down by KPMG during its time as the company’s auditor.

Strategic Timing for Change

The decision to appoint PwC comes amidst ongoing evaluations of governance and accountability which ResMed is undertaking. By introducing a new audit perspective through PwC, ResMed may enhance its financial strategies while adapting to market and operational changes. The timing indicates a proactive approach to strengthening internal financial oversight as the company progresses toward its fiscal objectives in the upcoming periods.

Upcoming Annual Meeting

ResMed's annual meeting of stockholders is scheduled for November 18, 2026. During this meeting, shareholders will address important governance changes, including the retirement of long-serving director Ron Taylor.

Peers Moving on This News